Abstract:Background There is consensus that postoperative adjuvant therapy is not recommended in patients with stage 1a non-small cell lung cancer (NSCLC). Meanwhile, it is still controversial whether postoperative adjuvant chemotherapy is recommended for NSCLC patients with T2aN0M0 (stage 1b). In some patients with stage 1b NSCLC without pleural invasion, tumor diameter was measured between 3 and 4 cm by preoperative imaging and less than 3 cm by postoperative pathology specimens. TNM staging in such patients is both radiologic stage 1b and pathologic stage 1a. Thoracic surgeons are often confused about whether such patients with NSCLC will require subsequent treatment and how the survival prognosis for this group of patients will be. Methods All data of radiographic TNM stage 1b patients who underwent radical R0 resection at the department of thoracic surgery, the First Affiliated Hospital of Soochow University between January 2013 and July 2017 were retrieved, and 208 patients were finally included in the study. Clinical data, including imaging data, pathology data, were obtained by reviewing the patients’ electronic medical records. Disease-free survival (DFS) and overall survival (OS) were obtained by telephone interview. Statistical analysis was performed using SPSS (SPSS 26.0 for windows, SPSS). Results A total of 208 patients were included in this study, 61 patients with T-stage migration (observation group) and 147 patients without T-stage migration (control group). There were significant statistical differences between the two groups in terms of preoperative FEV 1 /FVC and tumor diameter (specimens, CT and 3-dimensional measurements). Logistic regression results showed that lower FEV 1 /FVC and smaller CT measurements would make the patient's T stage more likely to migrate. Bland–Altman plots showed that tumor length measured by imaging was significantly higher than that measured by pathological specimens. Taking DFS as the outcome, the survival curve of the observation group was significantly better than that of the control group. Similarly, there was a significant difference in OS between the two groups. Conclusions For NSCLC patients whose preoperative imaging evaluation was stage 1b (tumor diameter more than 3 cm, no main bronchus, pleura, no atelectasis), the presence of lung tissue with smaller tumor diameter and/or higher air content may indicate that the postoperative pathological staging may be changed to stage 1a (tumor diameter less than 3 cm). These patients had better survival prognosis than those who did not undergo TNM stage change and were diagnosed with stage 1b non-small cell lung cancer before and after surgery.

[Small Cell Lung Cancer and TNM Staging].

The Lymph node ratio optimizes staging in patients with small intestinal neuroendocrine tumors.

Predictive Risk Factors for Lymph Node Metastasis in Patients with Small Size Non-Small Cell Lung Cancer.

Preoperative Lymph Node Assessment in Surgically Resected Pathologic T1 Lung Cancer Patients: Real World Clinical Practice in China.

Safety and Effectiveness of Neoadjuvant Immunotherapy Combined with Chemotherapy Followed by Surgical Resection in Patients with Stage I-IIIA Small-Cell Lung Cancer: a Retrospective Single-Arm Clinical Trial.

Validation of the 8th Edition Nodal Staging and Proposal of New Nodal Categories for Future Editions of the TNM Classification of Non-Small Cell Lung Cancer

NSCLC patients with a changing T grade after operation may represent a special subset of tumor staging

Real-world Surgical Treatment Patterns and Clinical Outcomes in Patients with Stages IA–IIIA Non-Small Cell Lung Cancer: a Retrospective Multicentric Observational Study Involving 11,958 Patients

A Real-World Observational Study To Explore Clinical Characteristics Of Chinese Patients With T1 Non-Small Cell Lung Cancer Complicated With Lymph Metastases.

A New Clinical Staging System for Esophageal Cancer to Predict Survival after Definitive Chemoradiation or Radiotherapy

Prognostic factors of patients with small cell lung cancer after surgical treatment

Clinical Analysis of Sixty-Four Patients with T1an2m0 Stage Non-Small Cell Lung Cancer Who Had Undergone Resection

Validation of the Eighth Edition of the TNM Staging System for Lung Cancer in 2043 Surgically Treated Patients With Non–small-cell Lung Cancer

The Revision of 8th Edition TNM Stage Criteria is More Accurate in Prediction Postoperative Survival for SCLC Patients

Study of prognostic predictors for non-small cell lung cancer

The 2002 AJCC TNM Classification is a Better Predictor of Primary Small Cell Esophageal Carcinoma Outcome Than the VALSG Staging System.

Comparison of the TNM9th and 8th editions for localized and locally advanced anal squamous cell carcinoma treated nonsurgically and proposal of a new stage grouping system

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groups in the Forthcoming (Ninth) Edition of the TNM Classification for Lung Cancer

The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations

Imaging of Lung Cancer Staging

Reconsidering the American Joint Committee on Cancer Eighth Edition TNM Staging Manual Classifications for T2b and T3 NSCLC